EUVIMEDEUVIMED entdecken
Open Access

Enfortumab vedotin demonstrates consistent efficacy in platinum- and ICI-refractory metastatic urothelial carcinoma patients irrespective of prior response: a multicenter real-world study

Shunsuke Watanabe, Yuichi Kitagawa, Asuka Uchiyama, Yuya Oishi, Hiroki Tanaka, Gaku Ishikawa, Shinya Watanabe, Eito Suzuki, Kyohei Watanabe, Yuto Matsushita, Hiromitsu Watanabe, Keita Tamura und 4 weitere

Central European Journal of Urology · 2026 · 79 (2) · 133-139

DOI: 10.5173/ceju.2025.0315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Central European Journal of Urology, 2026. Verfasst von Shunsuke Watanabe und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

enfortumab vedotinmetastatic urothelial carcinomaobjective response rateoverall survivalprior treatmentprogression-free survival

Autor:innen und Institutionen

  • Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Urology, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
  • Department of Urology, JA Shizuoka Kohseiren Enshu Hospital, Hamamatsu, Japan.
  • Department of Urology, Fujieda Municipal General Hospital, Fujieda, Japan.
  • Department of Urology, Iwata City Hospital, Iwata, Japan.
  • Department of Urology, Chutoen General Medical Center, Kakegawa, Japan.

Zitieren

APA

Watanabe, S., Kitagawa, Y., Uchiyama, A., Oishi, Y., Tanaka, H., Ishikawa, G., Watanabe, S., Suzuki, E., Watanabe, K., Matsushita, Y., Watanabe, H., Tamura, K., Matsumoto, R., Motoyama, D., Nagata, M., & Inamoto, T. (2026). Enfortumab vedotin demonstrates consistent efficacy in platinum- and ICI-refractory metastatic urothelial carcinoma patients irrespective of prior response: a multicenter real-world study. Central European Journal of Urology, 79(2), 133-139. https://doi.org/10.5173/ceju.2025.0315

Vancouver

Watanabe S, Kitagawa Y, Uchiyama A, Oishi Y, Tanaka H, Ishikawa G, et al. Enfortumab vedotin demonstrates consistent efficacy in platinum- and ICI-refractory metastatic urothelial carcinoma patients irrespective of prior response: a multicenter real-world study. Central European Journal of Urology. 2026;79(2):133-139. doi:10.5173/ceju.2025.0315

BibTeX
@article{Watanabe2026,
  author = {Watanabe, Shunsuke and Kitagawa, Yuichi and Uchiyama, Asuka and Oishi, Yuya and Tanaka, Hiroki and Ishikawa, Gaku and Watanabe, Shinya and Suzuki, Eito and Watanabe, Kyohei and Matsushita, Yuto and Watanabe, Hiromitsu and Tamura, Keita and Matsumoto, Rikiya and Motoyama, Daisuke and Nagata, Masao and Inamoto, Teruo},
  title = {Enfortumab vedotin demonstrates consistent efficacy in platinum- and ICI-refractory metastatic urothelial carcinoma patients irrespective of prior response: a multicenter real-world study},
  journal = {Central European Journal of Urology},
  year = {2026},
  volume = {79},
  number = {2},
  pages = {133--139},
  doi = {10.5173/ceju.2025.0315}
}
Kostenlos starten →